L&T Rating: Buy — A modest showing in the final quarter

By: |
Published: May 25, 2020 4:30 AM

FY21/22e EPS down 15% to factor in Covid-19; TP cut to Rs 1,394; ‘Buy’ maintained

L&T Technology Services (LTTS) reported USD revenue decline of 2% q-o-q in Q4FY20. Ebitda margin came in at ~ 19.8% (ex-one-off), in line with our estimate.L&T Technology Services (LTTS) reported USD revenue decline of 2% q-o-q in Q4FY20. Ebitda margin came in at ~ 19.8% (ex-one-off), in line with our estimate.

L&T Technology Services (LTTS) reported USD revenue decline of 2% q-o-q in Q4FY20. Ebitda margin came in at ~ 19.8% (ex-one-off), in line with our estimate. Revenue contraction is attributable to a 9% q-o-q dip in Plant Engineering (PE), overwhelming the robust 7% q-o-q growth in the medical devices business. Industrial products and Telecom & Hi-Tech were marginally down q-o-q.

Management refrained from guiding for FY21, but mentioned they expect revenue to slide in Q1FY21 and the recovery to take place thereafter. While we remain bullish on the long-term prospects of the fast-growing ER&D and believe LTTS is in a pole position to benefit thereof, the near-term pain from COVID-19 forces our hand to cut LTTS’s EPS by 15% each for FY21e and FY22e.

We are also slashing its target multiple from 20x to 17x, in line with our sectoral adjustment. Maintain Buy with a revised TP of Rs 1,394 (Rs 1,885 earlier) at 17x Q2FY22e EPS.

Covid-19 derails a recovering business: Ebitda margin eroded 160bps q-o-q to 18.5%, largely (~130bps) due to a one-off COVID-19-related CSR allocation. LTTS had just started recovering from its worst phase in Telecom & Hi-Tech, but COVID-19 and the crash in oil prices, respectively, have once again derailed the process, and that is a cause for worry. While management expects most businesses (except PE) to recover sharply in H2FY21 , the overall growth for FY21 at best would be flat, implying no revenue/earnings growth for the year.

Outlook: Temporary pain—Uncertainty continues to mar the outlook for ER&D revenue growth, now further undermined by the COVID-19 crisis. Nevertheless, we believe ER&D demand can bounce back and help LTTS realise its growth potential. The stock is trading at 12.8x FY22EE EPS. Retain ‘BUY/SO’.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Amul’s Panchamrit for temples; makes it easier, hygienic for devotees amid coronavirus
2Poco M2 Pro review: Best value phone under Rs 15,000
3Tata Power subsidiary completes sale of 3 ships for $212.76 million